A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to <sup>177</sup>Lutetium-DOTA-octreotate radionuclide therapy.
Journal Information
Full Title: Theranostics
Abbreviation: Theranostics
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Diagnostic Imaging
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing Interests: The authors have declared that no competing interest exists with respect to the current research. Outside this study RJH declares being shareholder in Telix Pharmaceuticals."
"The Molecular Genomics Core, the Advanced Centre for Cancer Cell Isolation and Flow Cytometry and the Centre for Advanced Histology and Microscopy (CAHM) at Peter MacCallum Cancer Centre. This research was supported by the Australian Cancer Research Foundation for the Molecular Genomics Core, the Advanced Centre for Cancer Cell Isolation and Flow Cytometry and the Centre for Advanced Histology and Microscopy (CAHM) at Peter MacCallum Cancer Centre. This work was supported by an Accelerator Award generously provided by the Neuroendocrine Tumor Research Foundation (NETRF)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025